Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
September 2016
-
Media Release
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image… -
Media Release
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
August 2016
-
Media Release
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving… -
Media Release
FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's… -
Media Release
Novartis convie plusieurs experts au Novartis International BioCamp afin de discuter des nouvelles technologies en matière de santé
La 13e édition de l'International Biotechnology Leadership Camp explore les nouvelles technologies susceptibles de révolutionner la recherche biomédicale et l'industrie pharmaceutique. Un programme… -
Media Release
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program… -
Media Release
Experten diskutieren am Novartis International BioCamp neue Technologien im Gesundheitsbereich
Im Zentrum des 13. International Biotechnology Leadership Camp steht das Potenzial neuer Technologien, die biomedizinische Forschung und die Pharmabranche grundlegend zu verändern Das interaktive… -
Media Release
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression… -
Media Release
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is… -
Media Release
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results… -
Media Release
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…